ESPR — Esperion Therapeutics Income Statement
0.000.00%
Last trade - 00:00- $920.39m
- $1.43bn
- $332.31m
Annual income statement for Esperion Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 228 | 78.4 | 75.5 | 116 | 332 |
| Cost of Revenue | |||||
| Gross Profit | 225 | 64.2 | 48.5 | 73.1 | 264 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 349 | 305 | 255 | 272 | 333 |
| Operating Profit | -121 | -227 | -180 | -156 | -0.516 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -144 | -269 | -234 | -209 | -51.7 |
| Net Income After Taxes | -144 | -269 | -234 | -209 | -51.7 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -144 | -269 | -234 | -209 | -51.7 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -144 | -269 | -234 | -209 | -51.7 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -5.22 | -8.85 | -3.52 | -2.03 | 0.017 |